Zambon and Vectans Pharma laboratories have entered into a partnership to ensure the marketing of Virpax®, Lauriad® Aciclovir 50mg, in France.
OTC switch approval in Sweden for Virono®50mg
Vectans Pharma is proud to announce that the Swedish Medical Products Agency has officially granted OTC status to its Lauriad® aciclovir treatment tablet for herpes labialis, Virono® 50mg, as a one-per-episode treatment.
« I am delighted to share with our partner Navamedic ASA, the approval decision of the Swedish MPA. This is a new major step for Virono® in Northern Europe. » states Vectans Pharma’s Director of Regulatory and Industrial Affairs, Jonathan Cohen.
Following Italy, France and Finland, Sweden is the fourth country to grant OTC status upon Lauriad®Aciclovir.
A brighter horizon for Oropharyngeal Candidiasis patients in Argentina
Celnova and Vectans Pharma announced they have signed an exclusive licensing agreement whereby Celnova will have the rights to commercialize in Argentina the once daily local buccal tablet of Miconazole Lauriad® for the treatment of oral thrush, Loramyc® 50mg.
« This partnership is an important milestone in our development plan and reinforces our international strategy . Next step, the Loramyc®’s MA submission. » said Jérôme Théron, CEO Vectans Pharma.
Loramyc® Marketing autorization granted in mexico !
Vectans Pharma is delighted to announce that COFEPRIS has granted Loramyc® Marketing Authorization on Mexican territory.
« We are so glad to achieve this milestone with our partner M8. It’s undoubtedly a new growth opportunity for Loramyc® and an advanced treatment for all Mexican patients suffering from OPC. » said Vectans Pharma’s Director of Regulatory and Industrial Affairs, Jonathan Cohen.
Happy 2024 !
Vectans Pharma wishes you a happy and healthy New Year!
OTC switch approval in Finland for Sitavig® 50mg
Vectans Pharma is proud to announce that Fimea (Finnish Medicines Agency) has granted OTC status to its Lauriad® aciclovir treatment tablet for herpes labialis, Sitavig® 50mg, as a one-per-episode treatment.
"I am pleased to share the news of Sitavig® receiving OTC status in Finland with our partner, Navamedic ASA . This achievement reflects our collective effort and provides a unique opportunity to offer patients access to an innovative treatment," states Vectans Pharma's Director of Regulatory and Industrial Affairs, Jonathan Cohen.
Following Italy and France, Finland is now the third country to grant OTC status upon Lauriad® Aciclovir, while we await further agreements in our global switch projects.
Exclusive agreement with the Menarini group and Berlin Chemie
Vectans Pharma is delighted to collaborate with the Menarini group and Berlin Chemie for the commercialization of Sitavig® in Italy and Austria.
Season's greetings
Vectans Pharma wishes you a happy and healthy New Year!
Vectans Pharma participated in a symposium about new treatments in Oropharyngeal Candidiasis
Dr Pierre Attali, our Chief Medical Officer, represented Vectans Pharma at the symposium organized by our Japanese partner Sosei Heptares about new treatments.
Copyright © VECTANS PHARMA